Get the Stockscreener App
114.23
1.61%
1.81
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $114.23, with a volume of 9.92M.
It is up +1.61% in the last 24 hours and down -1.47% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$112.42
Open:
$112.64
24h Volume:
9.92M
Relative Volume:
2.11
Market Cap:
$198.13B
Revenue:
$41.22B
Net Income/Loss:
$5.77B
P/E Ratio:
38.85
EPS:
2.94
Net Cash Flow:
$6.49B
1W Performance:
+0.75%
1M Performance:
-1.47%
6M Performance:
+7.19%
1Y Performance:
+6.36%
1-Day Range:
$112.52
$115.11
1-Week Range:
$111.28
$115.11
52-Week Range:
$99.71
$121.64
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
114.23 | 198.13B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
364.60 | 138.99B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
88.95 | 131.10B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
81.03 | 103.90B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.81 | 44.12B | 6.60B | 4.16B | 490.10M | 6.93 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
M&T Bank Corp Has $110.42 Million Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline - Seeking Alpha
Abbott Whistleblower's False Claims Suit is Revived, Narrowed - Bloomberg Law
Abbott Labs stock target increased, buy rating on strong product lineup - Investing.com
The Zacks Analyst Blog Highlights Veracyte, Omnicell, Masimo and Abbott Laboratories - Yahoo Finance
XTX Topco Ltd Sells 31,480 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories (NYSE:ABT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Abbott announces “first-in-world” leadless pacing procedures in left bundle branch area of heart - Cardiac Rhythm News
Implantable Loop Recorder Market Top Companies StudyAbbott - openPR
Syntax Research Inc. Makes New $2.28 Million Investment in Abbott Laboratories (NYSE:ABT) - MarketBeat
The Smartest Dividend Stocks to Buy With $500 Right Now - The Motley Fool
Biochips Market Huge Growth in Future Scope 2024-2031 | Abbott - openPR
Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Cardiologists perform world’s first leadless LBBAP procedures with Abbott pacemaker - Cardiovascular Business
Abbott completes first-in-human leadless left bundle branch area pacing procedures - Mass Device
Cardiac Biomarkers Market CAGR of 13.3% Size, Current Trends, Future Prospects By 2024-2031 | Abbott - EIN News
Are Abbott Laboratories' (NYSE:ABT) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness? - Yahoo Finance
Abbott Announces First-in-World Leadless Pacing Procedures in the Left Bundle Branch Area of the Heart - The Eastern Progress Online
Abbott Laboratories (ABT-N) QuotePress Release - The Globe and Mail
Abbott Laboratories stock outperforms competitors despite losses on the day - MarketWatch
How Abbott Labs Became a Dividend Growth Investor's Dream - MSN
How Abbott Labs Became A Dividend Growth Investor's Dream - Barchart
Abbott Laboratories a Top Ranked SAFE Dividend Stock With 2.1% Yield (ABT) - Nasdaq
Abbott Laboratories' SWOT analysis: medtech giant's stock faces litigation hurdles - Investing.com
Possible Bearish Signals With Abbott Laboratories Insiders Disposing Stock - Simply Wall St
B. Riley Wealth Advisors Inc. Sells 11,409 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Copley Financial Group Inc. Purchases New Shares in Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories (NYSE:ABT) Shares Sold by Retirement Systems of Alabama - MarketBeat
Abbott Laboratories stock underperforms Friday when compared to competitors - MarketWatch
Abbott Increases Dividend Again, Showcasing Decades of Reliable Shareholder Returns - Yahoo Finance
Abbott boosts quarterly dividend to 59 cents, up 7.3% - Investing.com
Abbott Declares Quarterly Common Dividend, Payable February 14, 2025 - Marketscreener.com
Abbott Labs Extends Royal Dividend Run With 7.3% Increase - Marketscreener.com
Abbott Increases Quarterly Dividend for 53rd Consecutive Year - The Eastern Progress Online
NEC Baby Formula Lawsuit - Lawsuit Information Center Blog
Tidal Investments LLC Purchases 25,052 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Franklin Resources Inc. Has $1.14 Billion Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott - Life Sciences Intellectual Property Review
Stock Yards Bank & Trust Co. Has $38.17 Million Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Dexcom suffers third successive patent loss in Abbott UPC dispute - IAM
Abbott (ABT) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Jim Cramer Says 'Keep Owning' This Energy Stock, Abbott Laboratories 'Legal Stuff' Is Behind Them - Benzinga
Abbott Laboratories (NYSE:ABT) Shares Acquired by Teachers Retirement System of The State of Kentucky - MarketBeat
Toronto Dominion Bank Sells 220,223 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Groupama Asset Managment Boosts Stock Holdings in Abbott Laboratories (NYSE:ABT) - MarketBeat
Baby Nutrition Market Size, Growth Status to 2033 Danone, Abbott - openPR
Lightning Round: Abbott Labs' legal trouble is largely behind it, says Jim Cramer - MSN
Cramer's Lightning Round: 'Keep owning' Energy Transfer - CNBC
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott Laboratories (NYSE:ABT) Shares Acquired by Geode Capital Management LLC - MarketBeat
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):